70 results
8-K
EX-99.1
AGRX
Agile Therapeutics Inc
9 Nov 23
Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
8:15am
protection for Twirla and our product candidates, the lingering effects of the COVID-19 pandemic on our commercialization efforts, clinical trials, supply
8-K
EX-99.1
6azae lkdx97624uwr
9 Aug 23
Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
8:10am
424B4
1sfb xipiluvu
24 May 23
Prospectus supplement with pricing info
4:05pm
8-K
EX-99.1
gkxw49y n0yudwhpi
11 May 23
Agile Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:15pm
8-K
EX-99.1
h6axht
28 Apr 23
Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023
4:40pm
8-K
0k5xai6 3gya5h83rsm
28 Apr 23
Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023
4:40pm
8-K
EX-99.1
uiwwracuw7lw3
7 Nov 22
Agile Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:10pm
8-K
EX-99.1
okezxmiv
7 Oct 22
Agile Therapeutics Announces Reorganization of Leadership Team
4:30pm
424B5
seoh44ulfmo2abfg7 b2
23 Aug 22
Prospectus supplement for primary offering
4:30pm